HC Wainwright reissued their neutral rating on shares of Kezar Life Sciences (NASDAQ:KZR – Free Report) in a research note issued to investors on Monday, Benzinga reports.
Kezar Life Sciences Trading Up 2.8 %
Shares of NASDAQ:KZR opened at $0.89 on Monday. The company has a 50 day moving average of $0.65 and a 200-day moving average of $0.69. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05. The firm has a market cap of $65.14 million, a P/E ratio of -0.64 and a beta of 0.21. Kezar Life Sciences has a twelve month low of $0.52 and a twelve month high of $1.14.
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Kezar Life Sciences will post -1.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kezar Life Sciences
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
See Also
- Five stocks we like better than Kezar Life Sciences
- Stock Analyst Ratings and Canadian Analyst Ratings
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is the Euro STOXX 50 Index?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.